Skip to content

CONEXUS PHARMA

Absorbed by REGON on 30-01-2018 KBO/BCE: BE 0538.611.801 subsidiary of REGON

Annual accounts 2016

micro format, filed on 01-08-2017, 1 day late
-€8,139
▲ €22,553
-€8,953
▲ €27,202
-€1,839
▲ €34,359
€14,075
▲ 767%
93.9%
▲ 29.2 percentage points
15.69
▲ 14.51

Turnover and EBIT margin are not published. The abbreviated or micro format does not require them.

Balance sheet

balance sheet total €15,718 on 31-12-2016
What the company ownsHow it is paid for

in euro

in euro

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend201620152014
Balance sheet: assets
20/58 15,71825,65352,797
20 6841,0261,368
21/28 -14,97619,968
21 -13,95018,600
29/58 15,03410,67732,829
40/41 -1,3801,197
41 -1,3801,197
54/58 15,0349,29731,631
Balance sheet: equity and liabilities
10/49 15,71825,65352,797
10/15 14,75916,59952,797
10/11 61,50061,50061,500
100 61,50061,50061,500
14 -46,741-44,901-8,703
17/49 9589,054-
42/48 9589,054-
44 -4,023-
440/4 -4,023-
45 6655,032-
450/3 6655,032-
47/48 293--
Income statement
9900 -8,139-30,691-2,889
630 3424,9924,992
640/8 473472835
9901 -8,953-36,156-8,716
75/76B 7,32241174
75 141174
76B 7,321--
65/66B 20884161
65 20884161
9903 -1,839-36,198-8,703
9904 -1,839-36,198-8,703
9905 -1,839-36,198-8,703
Appropriation of the result
9906 -46,741-44,901-8,703
Document PDFPDFPDF

Source: Annual accounts 2016 (PDF), filed on 01-08-2017.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank

2016 annual accounts filed 1 day after the deadline. Filed on 1 August 2017, deadline 31 July 2017 (7 months after the close on 31 December 2016, Companies Code art. 3:10). Source: NBB, 2017-38700323.

Financial year Type Filed Reference Document
31-12-2016 micro format 01-08-2017 2017-38700323 PDF
31-12-2015 abbreviated format 29-07-2016 2016-36100452 PDF
31-12-2014 abbreviated format 04-08-2015 2015-38600596 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend201620152014
-8,611-31,164-3,724
-1,497-31,206-3,711
-13,950023,250
5,737-22,335-
14,0751,623-
93.9%64.7%100.0%
15.691.18-
0.060.55-
-12.5%-218.1%-16.5%
-11.7%-141.1%-16.5%

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Insights on CONEXUS PHARMA

The operating result for 2016 is a loss of €8,953, smaller than the loss of €36,156 in 2015.

Debt's share of the balance-sheet total falls from 35.3% to 6.1%. Equity and debt are lower.